Michael Starck

869 total citations
12 papers, 493 citations indexed

About

Michael Starck is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Immunology. According to data from OpenAlex, Michael Starck has authored 12 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 5 papers in Public Health, Environmental and Occupational Health and 4 papers in Immunology. Recurrent topics in Michael Starck's work include Acute Lymphoblastic Leukemia research (5 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Complement system in diseases (2 papers). Michael Starck is often cited by papers focused on Acute Lymphoblastic Leukemia research (5 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Complement system in diseases (2 papers). Michael Starck collaborates with scholars based in Germany and France. Michael Starck's co-authors include Stefan Schwartz, Dieter Hoelzer, Albrecht Reichle, Andreas Viardot, Nicola Gökbuget, Hubert Serve, Matthias Stelljes, Knut Wendelin, Joachim Beck and Reingard Stuhlmann and has published in prestigious journals such as Blood, Scientific Reports and Journal of Hematology & Oncology.

In The Last Decade

Michael Starck

11 papers receiving 485 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Starck Germany 8 330 241 219 102 79 12 493
Olga Militano United States 12 134 0.4× 247 1.0× 176 0.8× 78 0.8× 54 0.7× 42 446
Pilar Bastida Spain 11 405 1.2× 277 1.1× 152 0.7× 224 2.2× 30 0.4× 19 572
Sergey N. Bondarenko Russia 9 132 0.4× 335 1.4× 112 0.5× 38 0.4× 144 1.8× 117 466
Woo‐Sung Min South Korea 14 136 0.4× 323 1.3× 104 0.5× 24 0.2× 61 0.8× 34 451
Regina Reutzel Germany 7 286 0.9× 295 1.2× 151 0.7× 86 0.8× 46 0.6× 8 493
Eun Sang Yi South Korea 11 110 0.3× 98 0.4× 87 0.4× 76 0.7× 34 0.4× 34 344
Cédric Pastoret France 8 134 0.4× 117 0.5× 88 0.4× 61 0.6× 145 1.8× 30 363
IM Chen United States 5 123 0.4× 309 1.3× 187 0.9× 39 0.4× 117 1.5× 8 506
Sameh Gaballa United States 12 87 0.3× 269 1.1× 169 0.8× 27 0.3× 98 1.2× 55 413
Meghan A. Higman United States 9 50 0.2× 198 0.8× 101 0.5× 33 0.3× 93 1.2× 15 338

Countries citing papers authored by Michael Starck

Since Specialization
Citations

This map shows the geographic impact of Michael Starck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Starck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Starck more than expected).

Fields of papers citing papers by Michael Starck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Starck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Starck. The network helps show where Michael Starck may publish in the future.

Co-authorship network of co-authors of Michael Starck

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Starck. A scholar is included among the top collaborators of Michael Starck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Starck. Michael Starck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Burmeister, Thomas, Daniela Gröger, Nicola Gökbuget, et al.. (2023). Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment. Scientific Reports. 13(1). 15167–15167. 6 indexed citations
2.
Stemmler, Hans‐Joachim, Fabian Hauck, Hendrik Schulze‐Koops, et al.. (2022). sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study. Blood Advances. 7(5). 832–844. 11 indexed citations
3.
4.
Schönermarck, Ulf, W Ries, Bernd Schröppel, et al.. (2019). Relative incidence of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy. Clinical Kidney Journal. 13(2). 208–216. 19 indexed citations
5.
Gökbuget, Nicola, Stefan Schwartz, Richard Reinhardt, et al.. (2017). Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL -negative acute lymphoblastic leukemia. Haematologica. 102(10). 1739–1747. 20 indexed citations
6.
Starck, Michael, et al.. (2014). Meningeal spread of blastic plasmacytoid dendritic cell neoplasm. European Journal Of Haematology. 93(2). 175–176. 5 indexed citations
7.
Bartram, Isabelle, Nicola Gökbuget, Cornelia Schlee, et al.. (2014). Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients. Journal of Hematology & Oncology. 7(1). 20 indexed citations
8.
Starck, Michael & C.‐M. Wendtner. (2014). Thrombotische Mikroangiopathien. DMW - Deutsche Medizinische Wochenschrift. 139(40). 1993–1996. 2 indexed citations
9.
10.
Gökbuget, Nicola, Joachim Beck, H. Diedrich, et al.. (2012). Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 120(10). 2032–2041. 321 indexed citations
11.
12.
Issels, Rolf D., Dominick Bossé, S. Abdel-Rahman, et al.. (1993). Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study.. PubMed. 31 Suppl 2. S233–7. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olga Militano Breakdown of academic impact, for papers by Pilar Bastida Breakdown of academic impact, for papers by Sergey N. Bondarenko Breakdown of academic impact, for papers by Woo‐Sung Min Breakdown of academic impact, for papers by Regina Reutzel Breakdown of academic impact, for papers by Eun Sang Yi Breakdown of academic impact, for papers by Cédric Pastoret Breakdown of academic impact, for papers by IM Chen Breakdown of academic impact, for papers by Sameh Gaballa Breakdown of academic impact, for papers by Meghan A. Higman
Rankless by CCL
2026